Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
01 mai 2024 07h00 HE
|
Chimerix, Inc.
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1...
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
24 avr. 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 avr. 2024 16h05 HE
|
Chimerix, Inc.
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards...
Chimerix Appoints Marc D. Kozin to Board of Directors
21 mars 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
29 févr. 2024 07h00 HE
|
Chimerix, Inc.
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204...
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
27 févr. 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
22 févr. 2024 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Appoints Lisa Decker to Board of Directors
29 déc. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
04 déc. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24 nov. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...